Results 41 to 50 of about 438,950 (335)

The power of microRNA regulation—insights into immunity and metabolism

FEBS Letters, EarlyView.
MicroRNAs are emerging as crucial regulators at the intersection of metabolism and immunity. This review examines how miRNAs coordinate glucose and lipid metabolism while simultaneously modulating T‐cell development and immune responses. Moreover, it highlights how cutting‐edge artificial intelligence applications can identify miRNA biomarkers ...
Stefania Oliveto, Nicola Manfrini, Stefano Biffo   +2 more
wiley   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Tumor Biology, 2017
The finding of epidermal growth factor receptor tyrosine kinase inhibitors, which reflects a classical process of translational research, is a critical milestone for non-small-cell lung cancer treatment.
Shaohua Cui, Liyan Jiang
doaj   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study

Middle East Journal of Cancer, 2013
Background: According to numerous studies, FMS-like tyrosine kinase 3, internal tandem duplication, and the D835 mutation are associated with a poor prognostic clinical outcome in acute myeloid leukemia patients. Detection of the FMS-like tyrosine kinase
Hind Dehbi, Yaya Kassogue, Sanaa Nasserddine, Asma Quessar, Sellama Nadifi   +4 more
doaj  

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Acta Dermato-Venereologica
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation.
Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo   +5 more
doaj   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj  

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap

Frontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa, Ivan Alvarez-Twose   +1 more
doaj   +1 more source

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase. [PDF]

PLoS ONE, 2015
The c-abl proto-oncogene encodes a nonreceptor tyrosine kinase that is found in all metazoans, and is ubiquitously expressed in mammalian tissues. The Abl tyrosine kinase plays important roles in the regulation of mammalian cell physiology.
Saadat U Aleem, Barbara P Craddock, W Todd Miller   +2 more
doaj   +1 more source

Computation of a Theoretical Membrane Phase Diagram, and the Role of Phase in Lipid Raft-Mediated Protein Organization [PDF]

, 2018
Lipid phase heterogeneity in the plasma membrane is thought to be crucial for many aspects of cell signaling, but the physical basis of participating membrane domains such as "lipid rafts" remains controversial. Here we consider a lattice model yielding a phase diagram that includes several states proposed to be relevant for the cell membrane ...
arxiv   +1 more source